<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336231</url>
  </required_header>
  <id_info>
    <org_study_id>COG-ANGIO</org_study_id>
    <nct_id>NCT01336231</nct_id>
  </id_info>
  <brief_title>Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer</brief_title>
  <acronym>COG-ANGIO</acronym>
  <official_title>Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients
      treated with anti-angiogenic for metastatic kidney cancer
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of fatigue, memory problems and attentional</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Assessing the impact of fatigue, memory problems and attentional induced by an anti-angiogenic and study their evolution over time in patients with metastatic kidney cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameters of quality of life</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Studying the different parameters of quality of life and their evolution over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disorders of cognitive functions</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Studying the correlations between disorders of cognitive functions and parameters of quality of life and fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biological disturbances</measure>
    <time_frame>up to 9 months after treatment</time_frame>
    <description>Search for biological disturbances may be related to fatigue and cognitive disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of anxiety and depression</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Assessing the impact of anxiety and depression at the waning of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>List of symptoms</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Compare the list of symptoms considered important by the patient compared to those recorded in the medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the sexuality</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>sess the impact on the sexuality of patients with the waning of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of different antiangiogenic agents</measure>
    <time_frame>up to 12 months after treatment</time_frame>
    <description>Compare the impact on quality of life and cognition side effects of different antiangiogenic agents used</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Metastatic Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>patients group</arm_group_label>
    <description>Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (e) Age (e) over 18 years

          -  Kidney cancer metastatic or locally advanced

          -  Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus,
             another molecule or developing or having obtained authorization in this indication)
             may be associated with interferon or combined together

          -  Proposed treatment in first line or second line

          -  Brain imaging not finding brain metastases

          -  Having signed the informed consent of study participation

          -  The patient may have received prior anti-angiogenic

        Exclusion Criteria:

          -  Cancer of the kidney other than primitive

          -  Previous history of cancer other than kidney cancer in complete remission for less
             than 5 years

          -  Patients under 18 years

          -  Patients whose treatment is associated with chemotherapy

          -  disorders of cognitive functions to existing treatment delivery

          -  Pathology psychiatric evolutionary

          -  Refusal of participation

          -  Patient unable to respond to cognitive tests

          -  Drug use

          -  Heavy drinking (WHO criteria)

          -  History of stroke

          -  History of head trauma

          -  Brain metastases known

          -  MMS below normal compared to existing standards for age and socio-cultural
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY-LOBBEDEZ, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>cognitive functions</keyword>
  <keyword>antiangiogenic agents</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

